Tolnaftate
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Tolnaftate: From Tinea Infections to Superficial Mycosis
One-Sentence Summary
Tolnaftate is a topical antifungal originally used for dermatophyte skin infections such as tinea pedis, tinea corporis and pityriasis versicolor. The TxGNN model's top-ranked prediction is ectothrix infectious disease (no supporting studies). The best-supported prediction is superficial mycosis, backed by 15 publications, including 2 randomised controlled trials and 1 systematic review, but no registered clinical trials. The superficial mycosis prediction largely confirms existing labelled use rather than representing a true new indication.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Tinea pedis, tinea corporis, tinea manuum, tinea barbae, pityriasis versicolor, dermatophytosis of the groin/perianal area and of the scalp or beard (from the knowledge graph; the Singapore licence records contain no indication text) |
| Predicted New Indication | Ectothrix infectious disease (rank 1; Hold). Superficial mycosis (rank 5) is the best-supported prediction. |
| TxGNN Prediction Score | 98.59% (ectothrix infectious disease); 98.48% (superficial mycosis) |
| Evidence Level | L5 for ectothrix infectious disease; L1 for superficial mycosis (based on published controlled studies, not registered Phase 3 trials) |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 2 |
| Recommended Decision | Hold for ectothrix infectious disease; Proceed with Guardrails for superficial mycosis |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data are not available in the data compiled for this report. Based on the general pharmacology of the drug, tolnaftate is a thiocarbamate antifungal that inhibits squalene epoxidase in dermatophytes, blocking ergosterol synthesis. It has proven efficacy in dermatophyte skin infections, and mechanistically it may apply to related fungal skin conditions.
Ectothrix infectious disease (rank 1) is a dermatophyte infection of the hair, closely related to the approved tinea indications. However, topical tolnaftate penetrates hair follicles poorly, and hair infections generally require systemic therapy. No trials or literature support this prediction, so it rests on the model score alone. The same limitation applies to the other deep or hair-related predictions: Majocchi granuloma, endothrix infectious disease and tinea profunda.
Superficial mycosis (rank 5) overlaps heavily with the approved indications (tinea pedis, corporis, cruris, versicolor). The literature includes a placebo-controlled comparison with griseofulvin and a double-blind comparison with clotrimazole. These studies are old, and tolnaftate's activity is not established for non-dermatophyte or deeper infections.
Predictions with no plausible mechanistic link include ophthalmic herpes zoster, infectious mononucleosis (both viral) and orbital cellulitis (typically bacterial, needing systemic antibiotics). These scores probably reflect network proximity to other infectious or skin diseases rather than pharmacology.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Evidence for the best-supported prediction, superficial mycosis:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 1090684 | 1975 | RCT (placebo-controlled) | J Invest Dermatol | Griseofulvin, tolnaftate and placebo compared in topical therapy of superficial dermatophytoses |
| 4619464 | 1974 | RCT (double-blind) | Postgrad Med J | Clotrimazole vs tolnaftate in superficial dermatophytoses |
| 10398626 | 1999 | Systematic review | BMJ | Efficacy and cost effectiveness of topical treatments for fungal infections of the skin and nails of the feet |
| 1379146 | 1992 | Review | Drugs | Diagnosis and treatment recommendations for superficial fungal skin infections |
| 778288 | 1976 | Review | J Invest Dermatol | Tolnaftate introduction described as a major advance for dermatophytosis |
| 5844107 | 1965 | Clinical study | Am J Dis Child | Tolnaftate in superficial fungus infections |
| 14288003 | 1964 | Clinical study | Antimicrob Agents Chemother | Effect of tolnaftate in superficial fungus infections |
| 14288002 | 1964 | Clinical study | Antimicrob Agents Chemother | Effect of tolnaftate on superficial mycotic infections |
| 4563192 | 1972 | Clinical study | Southeast Asian J Trop Med Public Health | Tolnaftate in superficial mycotic infections |
| 5952516 | 1966 | Clinical report | JAMA | Tolnaftate (Tinactin) as a topical agent for superficial fungal skin infections |
Other relevant publications:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 38874607 | 2024 | Review | Dermatologie | Tolnaftate listed among topical antifungals active against dermatophytes |
| 37415917 | 2023 | Review | Drugs Context | Updated review of tinea pedis |
| 32653607 | 2020 | In vitro study | Bioorg Chem | Tolnaftate inhibits ergosterol production and reduces Leishmania viability (preclinical only) |
| 16989127 | 2006 | Review | Therapie | Review of topical antifungal agents (cited for cutaneous candidiasis) |
| 1096122 | 1975 | Review | Practitioner | Clotrimazole cream as effective and acceptable as tolnaftate cream in dermatophytoses |
For cutaneous candidiasis (rank 3), the literature is indirect: general topical antifungal reviews and old tolnaftate reports. It does not establish efficacy against Candida, and azoles and polyenes remain the standard treatment.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN04473P | NAFTATE CREAM 1% w/w | Cream | Not stated in the licence record |
| SIN04429P | NAFTATE LOTION 1% w/v | Lotion | Not stated in the licence record |
Both products are single-ingredient, currently valid, and made by Sunward Pharmaceutical Private Limited.
Cytotoxicity
Not applicable. Tolnaftate is not an antineoplastic drug, so this section is omitted.
Safety Considerations
Please refer to the package insert for safety information. No drug interactions were found in the data compiled for this report, and no contraindicated diseases were identified from the knowledge graph.
Conclusion and Next Steps
Decision: Hold (ectothrix infectious disease and the other predictions); Proceed with Guardrails (superficial mycosis only)
Rationale:
- The top-ranked prediction, ectothrix infectious disease, has no trials or literature. Topical tolnaftate is also unlikely to penetrate hair follicles well, so these hair and deep infections generally need systemic therapy.
- Superficial mycosis has controlled studies and a systematic review, but they are old, and the prediction mostly restates existing labelled use. Predictions such as herpes zoster, infectious mononucleosis and orbital cellulitis have no plausible mechanism.
- The superficial mycosis L1 rating rests on published controlled studies, not registered Phase 3 trials, so it should be treated cautiously.
To proceed, the following is needed:
- The Singapore package insert, to confirm approved indications, warnings and contraindications (not available in the data compiled for this report)
- Mechanism of action data from DrugBank
- Review of the older RCTs' methodology and any recent comparative evidence in superficial mycosis
- For ectothrix and endothrix infections, Majocchi granuloma and tinea profunda: evidence of follicular penetration or clinical efficacy before any further consideration
- For cutaneous candidiasis: direct evidence against Candida compared with azoles or polyenes
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.